Relations of biomarkers representing distinct biological pathways to left ventricular geometry
- PMID: 19001021
- PMCID: PMC2747641
- DOI: 10.1161/CIRCULATIONAHA.108.817411
Relations of biomarkers representing distinct biological pathways to left ventricular geometry
Abstract
Background: Several biological pathways are activated concomitantly during left ventricular (LV) remodeling. However, the relative contribution of circulating biomarkers representing these distinct pathways to LV geometry is unclear.
Methods and results: We evaluated 2119 Framingham Offspring Study participants (mean age, 57 years; 57% women) who underwent measurements of biomarkers of inflammation (C-reactive protein), hemostasis (fibrinogen and plasminogen activator inhibitor-1), neurohormonal activation (B-type natriuretic peptide), and renin-angiotensin-aldosterone system (aldosterone and renin modeled as a ratio [ARR]) and echocardiography at a routine examination. LV geometry was defined on the basis of sex-specific distributions of LV mass (LVM) and relative wall thickness (RWT): normal (LVM and RWT <80th percentile), concentric remodeling (LVM <80th percentile but RWT >or=80th percentile), eccentric hypertrophy (LVM >or=80th percentile but RWT <80th percentile), and concentric hypertrophy (LVM and RWT >or=80th percentile). We related the biomarker panel to LV geometry using polytomous logistic regression adjusting for clinical covariates and used backwards elimination to identify a parsimonious set of biomarkers associated with LV geometry. Modeled individually, C-reactive protein, fibrinogen, plasminogen activator inhibitor-1, and ARR were related to LV geometry (P<0.01). In multivariable analyses, the biomarker panel was significantly related to altered LV geometry (P<0.0001). On backwards elimination, logARR alone was significantly and positively associated with eccentric (odds ratio per SD increment, 1.20; 95% confidence interval, 1.05 to 1.37) and concentric LV hypertrophy (odds ratio per SD increment, 1.29; 95% confidence interval, 1.06 to 1.58).
Conclusions: Our cross-sectional observations on a large community-based sample identified ARR as a key correlate of concentric and eccentric LV hypertrophy, consistent with a major role for the renin-angiotensin-aldosterone system in LV remodeling.
Similar articles
-
The natural history of left ventricular geometry in the community: clinical correlates and prognostic significance of change in LV geometric pattern.JACC Cardiovasc Imaging. 2014 Sep;7(9):870-8. doi: 10.1016/j.jcmg.2014.05.008. Epub 2014 Aug 13. JACC Cardiovasc Imaging. 2014. PMID: 25129518 Free PMC article.
-
Familial aggregation of left ventricular geometry and association with parental heart failure: the Framingham Heart Study.Circ Cardiovasc Genet. 2010 Dec;3(6):492-8. doi: 10.1161/CIRCGENETICS.110.941088. Epub 2010 Sep 30. Circ Cardiovasc Genet. 2010. PMID: 20884845 Free PMC article.
-
Cross-sectional relations of multiple biomarkers representing distinct biological pathways to plasma markers of collagen metabolism in the community.J Hypertens. 2009 Jun;27(6):1317-24. doi: 10.1097/HJH.0b013e328329fc20. J Hypertens. 2009. PMID: 19357531 Free PMC article.
-
Independent of left ventricular mass, circulating inflammatory markers rather than pressure load are associated with concentric left ventricular remodelling.Int J Cardiol. 2019 Jan 1;274:342-347. doi: 10.1016/j.ijcard.2018.09.059. Epub 2018 Sep 19. Int J Cardiol. 2019. PMID: 30287055
-
Changes in left ventricular geometry during antihypertensive treatment.Pharmacol Res. 2018 Aug;134:193-199. doi: 10.1016/j.phrs.2018.06.026. Epub 2018 Jun 26. Pharmacol Res. 2018. PMID: 29959031 Review.
Cited by
-
Parathormone Levels Are Independently Associated with the Presence of Left Ventricular Hypertrophy in Patients with Coronary Artery Disease.J Nutr Health Aging. 2016;20(6):659-64. doi: 10.1007/s12603-015-0649-y. J Nutr Health Aging. 2016. PMID: 27273357
-
Myocardial remodeling in hypertension.J Hum Hypertens. 2015 Jan;29(1):1-6. doi: 10.1038/jhh.2014.36. Epub 2014 May 8. J Hum Hypertens. 2015. PMID: 24804791 Review.
-
Determinants of left ventricular hypertrophy in hypertensive patients: identification of high-risk patients by metabolic, vascular, and inflammatory risk factors.Int J Angiol. 2013 Dec;22(4):223-8. doi: 10.1055/s-0033-1348880. Int J Angiol. 2013. PMID: 24436616 Free PMC article.
-
Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling.Circulation. 2011 Nov 1;124(18):e466-8. doi: 10.1161/CIRCULATIONAHA.111.067918. Circulation. 2011. PMID: 22042931 Free PMC article. Review. No abstract available.
-
Impaired myocardial perfusion reserve and fibrosis in Friedreich ataxia: a mitochondrial cardiomyopathy with metabolic syndrome.Eur Heart J. 2011 Mar;32(5):561-7. doi: 10.1093/eurheartj/ehq443. Epub 2010 Dec 14. Eur Heart J. 2011. PMID: 21156720 Free PMC article.
References
-
- Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet. 2006;367:356–367. - PubMed
-
- Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000;35:569–582. - PubMed
-
- Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol. 1995;25:879–884. - PubMed
-
- Cappola TP. Molecular Remodeling in Human Heart Failure. J Am Coll Cardiol. 2008;51:137–138. - PubMed
-
- Bloor CM, Nimmo L, McKirnan MD, Zhang Y, White FC. Increased gene expression of plasminogen activators and inhibitors in left ventricular hypertrophy. Mol Cell Biochem. 1997;176:265–271. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials